Therapeutic Indications

Cetuximab is indicated for:

Colorectal cancer EGFR + (epidermal growth factor receptor positive)

Irrespective of gender only Adults (18 years old or older)

Cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer:

  • in combination with irinotecan-based chemotherapy,
  • in first-line in combination with FOLFOX,
  • as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 250-400 mg/m² body surface area once a week

Squamous cell cancer of the head and neck

Irrespective of gender only Adults (18 years old or older)

Cetuximab is indicated for the treatment of patients with squamous cell cancer of the head and neck:

  • in combination with radiation therapy for locally advanced disease,
  • in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 250-400 mg/m² body surface area once a week

Contraindications

Active ingredient Cetuximab is contraindicated in the following cases:

Mutant RAS gene

No gender/age discrimination

The combination of cetuximab with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant RAS metastatic colorectal cancer (mCRC) or for whom RAS mCRC status is unknown.

Cetuximab should not be used in the treatment of colorectal cancer patients whose tumours have RAS mutations or for whom RAS tumour status is unknown. Results from clinical studies show a negative benefit-risk balance in tumours with RAS mutations. In particular, in these patients negative effects on progression-free survival (PFS) and overall survival (OS) were seen as add-on to FOLFOX4.